Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.79 |
| ▸ | S1PR5 | Q9H228 | 13/20 | 0.79 |
| ▸ | S1PR4 | O95977 | 10/20 | 0.79 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.79 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3133965 | 0.96 | S1PR1 (0.79) | S1PR1S1PR5S1PR4S1PR3 | |
| SCHEMBL5383882 | 0.88 | S1PR1 (1.00) | S1PR1S1PR5S1PR4S1PR3 | |
| SCHEMBL29151625 | 0.88 | S1PR1 (1.00) | S1PR1S1PR5S1PR4S1PR3 | |
| SCHEMBL3135332 | 0.88 | S1PR1 (0.61) | S1PR1S1PR5S1PR4S1PR3MAP4K4 | |
| SCHEMBL3134378 | 0.87 | S1PR1 (0.59) | S1PR1S1PR5S1PR4S1PR3MAP4K4 | |
| SCHEMBL3128427 | 0.86 | S1PR1 (0.61) | S1PR1S1PR5S1PR4S1PR3MAP4K4 | |
| SCHEMBL3136469 | 0.86 | S1PR1 (0.70) | S1PR1S1PR5S1PR4S1PR3MAP4K4 | |
| SCHEMBL3126053 | 0.86 | S1PR1 (0.60) | S1PR1S1PR5S1PR4S1PR3MAP4K4 | |
| SCHEMBL3127782 | 0.85 | S1PR1 (0.79) | S1PR1S1PR5S1PR4S1PR3MAP4K4 | |
| SCHEMBL3125972 | 0.85 | S1PR1 (0.59) | S1PR1S1PR5S1PR4S1PR3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1873153-B1 | 3-AZETIDINECARBOXYLIC ACID DERIVATIVES FOR USE AS IMMUNOSUPPRESSANTS | DAIICHI SANKYO CO LTD (JP) | 2010-07-07 | — | — | EP | claimed |
| US-7687491-B2 | Heterocyclic compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-03-30 | — | — | US | claimed |
| US-20080113961-A1 | Immunosuppressants with low toxicity; 1-({4-Methyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid for example; autoimmune diseases and transplant rejection; N-substituted azetidine, pyrrolidine or piperidine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-05-15 | — | — | US | claimed |
| EP-1873153-A1 | HETEROCYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-01-02 | — | — | EP | claimed |
| EP-1873153-B1 | 3-AZETIDINECARBOXYLIC ACID DERIVATIVES FOR USE AS IMMUNOSUPPRESSANTS | DAIICHI SANKYO CO LTD (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-7687491-B2 | Heterocyclic compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20080113961-A1 | Immunosuppressants with low toxicity; 1-({4-Methyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid for example; autoimmune diseases and transplant rejection; N-substituted azetidine, pyrrolidine or piperidine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1873153-A1 | HETEROCYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113961-A1 | Immunosuppressants with low toxicity; 1-({4-Methyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid for example; autoimmune diseases and transplant rejection; N-substituted azetidine, pyrrolidine or piperidine compounds | TPMT, AZI2, IDO1 | S1PR1 178/4885S1PR5 276/4885S1PR4 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.